CN1270721C - Rapid disintegration and rapid dissolution tablet containing kakonein - Google Patents
Rapid disintegration and rapid dissolution tablet containing kakonein Download PDFInfo
- Publication number
- CN1270721C CN1270721C CN 200410071712 CN200410071712A CN1270721C CN 1270721 C CN1270721 C CN 1270721C CN 200410071712 CN200410071712 CN 200410071712 CN 200410071712 A CN200410071712 A CN 200410071712A CN 1270721 C CN1270721 C CN 1270721C
- Authority
- CN
- China
- Prior art keywords
- tablet
- quick
- puerarin
- sodium
- disintegrate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
The present invention relates to a rapid disintegration and rapid dissolution tablet containing the active component of kakonein, which belongs to the field of a medicinal preparation. The rapid disintegration and rapid dissolution tablet is prepared by mixing the active component of kakonein, disintegrant, filling agent, correctant, lubricating agent, effervescent, binding agent and colorant by a pressing technology. Each tablet contains 10 to 100 mg of kakonein, the dosage of the disintegrant accounts for 2 to 20% of the total weight of the tablet, and solubilizer accounts for 1 to 10% of the total weight of the tablet. The tablet of the present invention is disintegrated in less than one minute by contacting saliva in a mouth cavity, and more than 80% of the total amount of the tablet is dissolved in three minutes. The present invention has the advantages of rapid disintegration, convenient use and high dissolution speed.
Description
Technical field
The invention belongs to field of pharmaceutical preparations, relate to a kind of rapid disintegration and rapid dissolution tablet, be specifically related to a kind of rapid disintegration and rapid dissolution tablet that contains the active component puerarin.
Background technology
Oral cavity quickly disintegrating tablet (orally fast-disintegrating tablet, ororally rapidly-disintegrating tablet) is a kind of new pharmaceutical preparation of rising both at home and abroad over past ten years, has taking convenience, disintegrate is rapid, rapid-action, bioavailability is high characteristics.The oral cavity rapid disintegration tablet can not need water, but only just administration under the effect of a small amount of saliva.In general, the oral cavity rapid disintegration tablet contacts in the oral cavity after the saliva should disintegrate in 1 minute, and after the disintegrate, absorption has been accelerated in medicine stripping promptly or be dispersed into granule, makes onset rapid.This dosage form is applicable to: (1) has patient such as the child and the elderly patients of dysphagia; (2) the digestive tract disease patient causes and can't swallow or swallowing act causes serious vomiting reaction; (3) bed patient or work busy personage or traveller are especially when can't obtaining water; (4) in the time of need making the rapid onset of medicine.Some disease such as cardiovascular disease, asthma, allergy, pain etc. all require quick administration.
The oral cavity rapid disintegration tablet is mainly by freeze-drying and pressing preparation.It is that active constituents of medicine and various adjuvant or additive are made solution or suspension that freeze-drying prepares oral rapidly disintegrating chip technology (Zydis), inject the mould of definite shape, be frozen into solid rapidly, decompression makes water sublimed again, thereby form the tablet with loose structure, this kind tablet configuration is loose, interior rich small spaces, the dissolving that can absorb water rapidly generally can reach in 10 seconds in intraoral disintegration time.At present, the drug main that adopts this technology to make the oral cavity rapid disintegration tablet will comprise: (J PharmPharmacol such as oxazepam, lorazepam, piroxicam, loperamide, famotidine, loratadine, enalapril, phenylpropanolamine/brompheniramine, ondansetron, Lizakuputan benzoate (Rizatriptan Benzoate), domperidone, nitroglycerin, isosorbidi dinitras, nifedipine, difenidol hydrochloride, meclozine hydrochloride, 1998,50:375; PLA's Acta Pharmaceutica Sinica, 2000,16:206).But this method needs special freeze drying equipment, complex process, and the cost height, the tablet mechanical strength that makes is relatively poor.The oral cavity quickly disintegrating tablet porosity of pressing preparation is little, and disintegrate is slow slightly.But preparation technology is simple, and mechanical strength is better.At present, the medicine that adopts pressing to make oral cavity quick disintegrating slice mainly contains Zolmitriptan (zomitriptan), that Puli of rice, baclofen, carbidopa/levodopa, carisoprodol (carisprodol) etc.
Existing report, the disintegration time of the quickly disintegrating tablet of pressing preparation depends mainly on selected disintegrating agent.Now normal adopt cross-linked carboxymethyl cellulose sodium with good disintegrating property, polyvinylpolypyrrolidone etc. (foreign medical science pharmacy fascicle, 1998,25:293).The consumption of filler and disintegrating agent has material impact to disintegration time, the consumption of disintegrating agent reach as high as sheet heavy more than 15%.Filler is used lactose, mannitol, microcrystalline Cellulose etc. always.Medicine with bitterness can adopt the powder coating method earlier medicine to be hidden flavor, and repress is made oral cavity quick disintegrating slice (CNl328446A).
For medicine easily molten in the water, make rapid disintegration tablet after because stripping is non-speed limit process, so the stripping of medicine is very fast, makes medicine promptly begin to absorb in the oral cavity, and is rapid-action.For insoluble drug in the water, because stripping is the speed limit process, though the rapid disintegration tablet of making disintegrate rapidly, medicine is to exist with the crystallization original shape behind the disintegration of tablet, and being absorbed after the stripping still needs a process again, so onset is slower.The oral cavity rapid disintegration tablet of report mostly is moisture soluble drug greatly at present.Insoluble drug prepares the oral cavity rapid disintegration tablet and has following difficulty, and (1) medicine itself is hydrophobic, influences tablet suction disintegrate; (2) medicine is suspension behind disintegration of tablet, and onset is slow.
Puerarin is the monomer that extracts from the dry root of legume pueraria lobata a---isoflavone compounds, has been widely used in cardiovascular and cerebrovascular disease and other treatment of diseases at present.Principal indication comprises coronary heart disease, ischemic cerebrovascular, diabetes complicated microangiopathies, peripheral arterial ischemic pathological changes, sudden deafness etc.The patient mostly is the old people, owing to be subjected to the influence of cardiovascular and cerebrovascular disease, how with in the action inconvenience.Puerarin is a poorly water soluble drugs, and at present the peroral dosage form of using clinically is a coated tablet, and its external disintegration time is 30 ~ 60 minutes, and dissolution 2 hours is less than 10%.The medicine stripping is slow, and it is slow to absorb, so onset is slower, owing to absorb not exclusively, is difficult to guarantee curative effect.
Summary of the invention
The object of the present invention is to provide a kind of oral cavity rapid disintegration and rapid dissolution tablet that contains the active component puerarin, making things convenient for administration, and stripping is accelerated, absorb quickening.More properly say, the rapid disintegration and rapid dissolution tablet that the present invention relates to be a kind of can disintegrate fast in the oral cavity contacts saliva 1 minute, more than 80% of 3 minutes stripping total amounts need not swallowed, onset is rapid, oral drug preparation easy to use.
The rapid disintegration and rapid dissolution tablet that the present invention relates to is an active component with the puerarin, also contains the mixture of the excipient that comprises potent disintegrating agent and potent solubilizing agent.
Tablet of the present invention adopts the pressing preparation, and to utilize saliva in the oral cavity be the effect of disintegratable in order to reach, and adopts pharmaceutics technological selection prescription, makes it can be in the oral cavity not reach disintegrate fast in time of 1 minute with saliva, is preferably less than 30 seconds.The invention has the advantages that when taking, need not drink water that only the effect by saliva just can make disintegration of tablet and can add solubilizing agent stripping is accelerated.
The effective ingredient puerarin of tablet of the present invention and the weight ratio of excipient are 1: 1 ~ 1: 50, are preferably 1: 5 ~ 1: 10.
The mixture of the excipient of described potent disintegrating agent and potent solubilizing agent is the mixture that comprises filler, disintegrating agent, solubilizing agent, sweeting agent, binding agent, lubricant, coloring agent and/or effervescent excipient, plays respectively and keeps sheet weight, sheet shape, disintegrate, solubilising, bonding, painted, moistening, flavored action.
Wherein filler is 40% ~ 90% of a tablet total weight, is preferably 60 ~ 80%.Can select microcrystalline Cellulose, mannitol, lactose, xylitol, sucrose, glucose, starch, pregelatinized Starch, calcium sulfate, calcium carbonate, calcium phosphate, light magnesium oxide and composition thereof for use, wherein preferably microcrystalline cellulose, lactose and mannitol.Tablet appearance of the present invention is bright and clean, and compressibility is good, and tablet can reach suitable hardness, and described mannitol has sweet flavor because of when dissolving heat absorption, therefore has refrigerant tasty and refreshing sensation in the oral cavity.Described microcrystalline Cellulose has the effect of filler, disintegrating agent, binding agent, lubricant concurrently, can improve the compressibility of tablet powder body.
Tablet of the present invention contains disintegrating agent, and its consumption is 2% ~ 20% of a tablet total weight, is preferably 5% ~ 15%.The optional polyvinylpolypyrrolidone of described disintegrating agent, cross-linking sodium carboxymethyl cellulose, carboxymethyl starch sodium, hydroxypropyl starch, its mixture of low-substituted hydroxypropyl cellulose can expand rapidly behind the chance water, and the quick disintegrate of tablet is burst apart.The disintegration time of tablet shortens with the consumption increase of disintegrating agent.The adding of disintegrating agent can be undertaken by interior addition, outer addition and inside and outside addition.
Tablet of the present invention also can contain the power that effervescent is disintegrate.Its consumption accounts for 0% ~ 40% of tablet total weight, is preferably 1% ~ 10%.
Described effervescent is made up of organic bronsted lowry acids and bases bronsted lowry.Wherein organic acid can be citric acid, tartaric acid, succinic acid, lactic acid, glycolic, oxalic acid, gluconic acid, Citric anhydride, succinic anhydrides, winestone anhydride and composition thereof.Wherein alkali can be sodium carbonate, sodium bicarbonate, potassium carbonate, potassium bicarbonate, calcium carbonate, calcium bicarbonate, magnesium carbonate, brium carbonate and composition thereof.
Puerarin is an insoluble drug in the tablet of the present invention, with the oral problem that often has stripping of solid form, adds solubilizing agent or cosolvent in the tablet of the present invention to increase stripping.Its consumption is 1% ~ 20% of a tablet total weight, is preferably 3% ~ 10%.Described solubilizing agent can comprise poloxamer (polyoxyethylene-polyoxypropylene copolymer), Tweens, spans, sodium lauryl sulphate, sodium hexadecyl sulfate, sodium stearyl sulfate, dioctyl sodium sulfosuccinate, dihexyl sodium sulfosuccinate, dodecyl sodium sulfate, dodecylbenzene sodium sulfonate, sodium glycocholate, sodium taurocholate, beta-schardinger dextrin-and hydroxypropyl.Described cosolvent comprises nicotiamide, benzoic acid, sodium benzoate and composition thereof.Solubilizing agent or cosolvent can increase the moistening of puerarin, accelerate dissolution rate, guarantee the performance of drug effect.Tablet of the present invention is tested by dissolution test method (two appendix of Pharmacopoeia of the People's Republic of China version in 2000) in intellectual drug digestion instrument (Radio Factory of Tianjin Univ.), and dissolution was not less than 80% in 3 minutes.
Can contain binding agent or wetting agent in the excipient of tablet of the present invention.Especially be selected from starch slurry, polyvidone rubber cement, hypromellose rubber cement, methylcellulose (sodium) rubber cement, carboxymethyl cellulose (sodium) rubber cement, water, ethanol and composition thereof.The kind of described binding agent and consumption and usage have a significant impact the disintegrating property and the stripping of tablet.Can be the dry filler with adhesion characteristic, be suitable for becoming tablet with the direct compression prepared, can also be aqueous rubber cement, solution, has bonding or wetting action.
Can contain sweeting agent and optional colorant, aromatic, lubricant in the excipient of tablet of the present invention.
Sweeting agent especially is selected from aspartame, acesulfame potassium, saccharin sodium, Neohesperidin Dihydrochalcone and composition thereof.Consumption is 1% ~ 10% of a tablet total weight, is preferably 2% ~ 5%.
Tablet of the present invention has suitable hardness, and this hardness can tolerate the various processing under the routine operation condition and its character do not produced bigger influence between 20 ~ 70 newton usually.
Tablet of the present invention can be by the following method or suitable method preparation on other pharmaceutics.Earlier active component puerarin and various excipient were pulverized 80 eye mesh screens, after pressing the formula ratio precision weighing, with puerarin and filler, disintegrating agent, solubilizing agent, sweeting agent, coloring agent mix homogeneously, add suitable amount of adhesive or wetting agent, make wet granular, must do granule after the uniform temperature drying, add lubricant, compacting forms.
The specific embodiment
Embodiment 1 is the rapid disintegration and rapid dissolution tablet that contains puerarin of filler with the microcrystalline Cellulose
By following set of dispense ratio preparation tablet.
| Raw material and adjuvant | Prescription 1 | Prescription 2 | Prescription 3 |
| Puerarin | 50.00mg | 50.00mg | 50.00mg |
| Microcrystalline Cellulose | 65.61mg | 44.39mg | 70.00mg |
| Lactose | 150.00mg | 150.00mg | 150.00mg |
| Polyvinylpolypyrrolidone | 44.14mg | 25.86mg | 40mg |
| Radix Asparagi acyl phenylalanine first | 8.00mg | 8.00mg | 8.00mg |
| Ester | |||
| Citric acid | 5.00mg | 5.00mg | 5.00mg |
| Sodium bicarbonate | 6.00mg | 6.00mg | 6.00mg |
| Poloxamer | 2.00mg | 2.00mg | 2.00mg |
| Ferrum oxide (red) | 0.001％ | 0.001％ | 0.001％ |
| 5% starch slurry | Convention amount | Convention amount | Convention amount |
| Magnesium stearate | 1％ | 1％ | 1％ |
Preparation as follows.
Active component puerarin in the prescription and listed each excipient are crossed 80 mesh sieves respectively.
With puerarin, microcrystalline Cellulose, lactose, polyvinylpolypyrrolidone, aspartame, poloxamer, citric acid, sodium bicarbonate mix homogeneously.
Add 5% starch slurry, the system soft material, 20 mesh sieves push the granulation of sieving.
Wet granular was put 60 ℃ of freeze-day with constant temperature 2 hours.
Dried granule 20 mesh sieve granulate.
Add magnesium stearate, mixing.
Compacting forms on the tablet machine, and average sheet heavily is between 300mg ~ 350mg, and tensile strength is between 20 ~ 50 newton.
Adopt the bibliographical information method to carry out the oral cavity disintegration tablet inspection of disintegration, (PowderTechnology, 2002,122: 188 ~ ~ 198).Dissolution method is undertaken by dissolution method first method among two appendix XC of Pharmacopoeia of the People's Republic of China version in 2000, and its 3 minutes dissolutions are greater than 80%.
Table 1 is check result disintegration of puerarin oral cavity disintegration tablet among the embodiment 1.Table 2 is that the dissolution (%) of the quick stripping sheet of the quick disintegrate in puerarin oral cavity is investigated the result.
Table 1
| Filled a prescription for 1 (second) | Filled a prescription for 2 (seconds) | Filled a prescription for 3 (seconds) | |
| 1 | 32 | 24 | 20 |
| 2 | 23 | 27 | 23 |
| 3 | 22 | 30 | 20 |
| 4 | 28 | 34 | 27 |
| 5 | 25 | 24 | 23 |
| 6 | 29 | 40 | 21 |
| X±SD | 26.50±3.83 | 29.83±1.83 | 22.33±2.66 |
Table 2
| Time (minute) | The cup number | X±SD | ||
| 1 | 2 | 3 | ||
| 3 | 82.35 | 82.78 | 83.16 | 82.76±0.41 |
| 5 | 91.34 | 88.87 | 87.55 | 89.25±1.92 |
| 15 | 95.77 | 92.49 | 91.82 | 93.36±2.11 |
| 45 | 94.85 | 92.46 | 91.52 | 92.94±1.72 |
Embodiment 2: containing mannitol is the puerarin oral cavity rapid disintegration tablet of filler
Than the preparation tablet, the dosage of puerarin is 25 ~ 75mg by following set of dispense.
| Raw material and adjuvant | Prescription .4 | Prescription 5 | Prescription 6 |
| Puerarin | 25.00mg | 50.00mg | 75.00mg |
| Mannitol | 110.00mg | 170.00mg | 200.00mg |
| Polyvinylpolypyrrolidone | 25.00mg | 40.00mg | 60.00mg |
| Aspartame | 8.00mg | 8.00mg | 8.00mg |
| Citric acid | 5.00mg | 5.00mg | 5.00mg |
| Sodium bicarbonate | 6.00mg | 6.00mg | 6.00mg |
| Poloxamer | 2.00mg | 2.00mg | 2.00mg |
| Ferrum oxide (red) | 0.001％ | 0.001％ | 0.001％ |
| 5% starch slurry | Convention amount | Convention amount | Convention amount |
| Magnesium stearate | 1％ | 1％ | 1％ |
Preparation process is with embodiment 1.
Compacting forms on the tablet machine, and average sheet heavily is between .190mg ~ 370mg, and tensile strength is between 20 ~ 50 newton.Because mannitol heat absorption when dissolving has the algefacient sensation when Orally disintegrating, help to improve the taste of tablet.
Disintegration and dissolution test method are with embodiment 1.
Table 3 is puerarin disintegration time of orally disintegrating tablets and dissolution test results among the embodiment 2.
Table 3
| Prescription 4 | Prescription 5 | Prescription 6 | |
| Disintegration time (second) | 18.48±3.37 | 26.89±2.66 | 30.12±4.62 |
| 3 minutes dissolutions | ＞80％ | ＞80％ | ＞80％ |
Embodiment 3: the puerarin oral cavity disintegration tablet that contains saccharide and starch based.
By following set of dispense ratio preparation tablet.
| Raw material and adjuvant | Prescription .7 | Prescription 8 | Prescription 9 |
| Puerarin | 50.00mg | 50.00mg | 50.00mg |
| Glucose | 50.00mg | 25.00mg | 75.00mg |
| Pregelatinized Starch | 50.00mg | 75.00mg | 25.00mg |
| Carboxymethyl starch sodium | 40.00mg | 40mg | 40mg |
| Aspartame | 8.00mg | 8.00mg | 8.00mg |
| Citric acid | 5.00mg | 5.00mg | 5.00mg |
| Sodium bicarbonate | 6.00mg | 6.00mg | 6.00mg |
| Poloxamer | 2.00mg | 2.00mg | 2.00mg |
| Ferrum oxide (red) | 0.001％ | 0.001％ | 0.001％ |
| 5% starch slurry | Convention amount | Convention amount | Convention amount |
| Magnesium stearate | 1％ | 1％ | 1％ |
Preparation process is with embodiment 1.As filler and disintegrating agent, low lattice are cheap with saccharide and starch based.
Compacting forms on the tablet machine, and average sheet heavily is about 230mg, and tensile strength is between 20 ~ 50 newton.
Disintegration and dissolution test method are with embodiment 1.
Table 4 is puerarin disintegration time of orally disintegrating tablets and dissolution test results among the embodiment 3.
Table 4
| Prescription 7 | Prescription 8 | Prescription 9 | |
| Disintegration time (second) | 35.25±1.65 | 43.79±2.08 | 27.68±3.92 |
| 3 minutes dissolutions | ＞80％ | ＞80％ | ＞80％ |
Embodiment 4: the puerarin oral cavity disintegration tablet that contains low-substituted hydroxypropyl cellulose.
By following set of dispense ratio preparation tablet.
| Raw material and adjuvant | Prescription 10 |
| Puerarin | 50.00mg |
| Microcrystalline Cellulose | 70.00mg |
| The low substituted hydroxy-propyl fiber | 150.00mg |
| Plain | |
| Saccharin sodium | 10.00mg |
| Tartaric acid | 5.00mg |
| Magnesium carbonate | 6.00mg |
| Poloxamer | 2.00mg |
| Ferrum oxide (red) | 0.001％ |
| 5% starch slurry | Convention amount |
| Magnesium stearate | 1％ |
Preparation process is with embodiment 1.
Compacting forms on the tablet machine, and average sheet heavily is about 300mg, and tensile strength is between 20 ~ 50 newton.
Disintegration and dissolution test method are with embodiment 1.Disintegration time is about 32.37 ± 3.35 seconds, and dissolution 3 minutes is greater than 80%.
Embodiment 5: the puerarin oral cavity disintegration tablet that contains surfactant.
By following set of dispense ratio preparation tablet.
| Raw material and adjuvant | Prescription 11 |
| Puerarin | 50.00mg |
| Microcrystalline Cellulose | 70.00mg |
| Low-substituted hydroxypropyl cellulose | 150.00mg |
| Saccharin sodium | 10.00mg |
| Tartaric acid | 5.00mg |
| Magnesium carbonate | 6.00mg |
| Sodium lauryl sulphate | 4.00mg |
| Ferrum oxide (red) | 0.001％ |
| 5% starch slurry | Convention amount |
| Magnesium stearate | 1％ |
Preparation process is with embodiment 1.
Compacting forms on the tablet machine, and average sheet heavily is about 300mg, and tensile strength is between 20 ~ 50 newton.
Disintegration and dissolution test method are with embodiment 1.Disintegration time is about 26.55 ± 3.40 seconds, and dissolution 3 minutes is greater than 80%.
The present invention describes by above description and embodiment, more than is described as nonrestrictively, does not limit claim scope of the present invention.
Claims (17)
1, a kind of tablet that contains the quick stripping of quick disintegrate of puerarin, it is characterized in that with the puerarin being active component, the mixture that also contains the excipient that comprises potent disintegrating agent and potent solubilizing agent, the weight ratio of the mixture of described active component and excipient is 1: 1 ~ 1: 50, and the dosage of described active component puerarin is 10 ~ 150mg/ sheet; The mixture of described excipient comprises filler, disintegrating agent, solubilizing agent, sweeting agent, binding agent, lubricant, coloring agent and/or effervescent, and wherein the disintegrating agent consumption is 2% ~ 20% of a tablet total weight, and its consumption of solubilizing agent is 1% ~ 10% of a tablet total weight.
2, by the described tablet that contains the quick stripping of quick disintegrate of puerarin of claim 1, the dosage that it is characterized in that described active component puerarin is 20 ~ 100mg/ sheet.
3, by the described tablet that contains the quick stripping of quick disintegrate of puerarin of claim 1, the weight ratio that it is characterized in that the mixture of described active component and excipient is 1: 5 ~ 1: 10.
4, by the described tablet that contains the quick stripping of quick disintegrate of puerarin of claim 1, it is characterized in that described disintegrating agent is selected from polyvinylpolypyrrolidone, cross-linking sodium carboxymethyl cellulose, carboxymethyl starch sodium, hydroxypropyl starch, low-substituted hydroxypropyl cellulose and composition thereof.
5, by claim 1 or the 4 described tablets that contain the quick stripping of quick disintegrate of puerarin, it is characterized in that described disintegrating agent is polyvinylpolypyrrolidone and/or cross-linking sodium carboxymethyl cellulose.
6, by claim 1 or the 4 described tablets that contain the quick stripping of quick disintegrate of puerarin, it is characterized in that described disintegrating agent consumption is 5% ~ 15% of a tablet total weight.
7, by the described tablet that contains the quick stripping of quick disintegrate of puerarin of claim 1, it is characterized in that described filler is microcrystalline Cellulose, mannitol, lactose, xylitol, sucrose, glucose, starch, pregelatinized Starch, calcium sulfate, calcium carbonate, calcium phosphate, light magnesium oxide and composition thereof.
8, by claim 1 or the 7 described tablets that contain the quick stripping of quick disintegrate of puerarin, it is characterized in that described filler is microcrystalline Cellulose, mannitol and lactose.
9, by claim 1 or the 7 described tablets that contain the quick stripping of quick disintegrate of puerarin, it is characterized in that described filler accounts for 40% ~ 90% of tablet total weight.
10, by claim 1 or the 7 described tablets that contain the quick stripping of quick disintegrate of puerarin, it is characterized in that described filler accounts for 60 ~ 80% of tablet total weight.
11, by the described tablet that contains the quick stripping of quick disintegrate of puerarin of claim 1, it is characterized in that described sweeting agent is aspartame, acesulfame potassium, saccharin sodium, Neohesperidin Dihydrochalcone and composition thereof.
12, by claim 1 or the 11 described tablets that contain the quick stripping of quick disintegrate of puerarin, it is characterized in that described sweeting agent consumption is 1% ~ 10% of a tablet total weight.
13, by the described tablet that contains the quick stripping of quick disintegrate of puerarin of claim 1, it is characterized in that described effervescent is made up of organic acid and alkali, wherein organic acid comprises citric acid, tartaric acid, succinic acid, lactic acid, glycolic, oxalic acid, gluconic acid, Citric anhydride, succinic anhydrides, winestone anhydride and composition thereof, and wherein alkali comprises sodium carbonate, sodium bicarbonate, potassium carbonate, potassium bicarbonate, calcium carbonate, calcium bicarbonate, magnesium carbonate, brium carbonate and composition thereof.
14, by claim 1 or the 13 described tablets that contain the quick stripping of quick disintegrate of puerarin, it is characterized in that the consumption of described effervescent accounts for 0% ~ 40% of tablet total weight.
15, by the described tablet that contains the quick stripping of quick disintegrate of puerarin of claim 1, it is characterized in that described solubilizing agent comprises poloxamer, Tweens, spans, sodium lauryl sulphate, sodium hexadecyl sulfate, sodium stearyl sulfate, dioctyl sodium sulfosuccinate, dihexyl sodium sulfosuccinate, dodecyl sodium sulfate, dodecylbenzene sodium sulfonate, sodium glycocholate, sodium taurocholate, beta-schardinger dextrin-, hydroxypropyl, nicotiamide, benzoic acid, sodium benzoate and composition thereof.
16, by claim 1 or the 15 described tablets that contain the quick stripping of quick disintegrate of puerarin, it is characterized in that described solubilizing agent is poloxamer and sodium lauryl sulphate.
17, by claim 1 or the 15 described tablets that contain the quick stripping of quick disintegrate of puerarin, it is characterized in that its consumption of described solubilizing agent is 2% ~ 5% of a tablet total weight.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410071712 CN1270721C (en) | 2003-07-23 | 2004-07-16 | Rapid disintegration and rapid dissolution tablet containing kakonein |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN03141777.9 | 2003-07-23 | ||
| CN03141777 | 2003-07-23 | ||
| CN 200410071712 CN1270721C (en) | 2003-07-23 | 2004-07-16 | Rapid disintegration and rapid dissolution tablet containing kakonein |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1575798A CN1575798A (en) | 2005-02-09 |
| CN1270721C true CN1270721C (en) | 2006-08-23 |
Family
ID=34593049
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200410071712 Expired - Fee Related CN1270721C (en) | 2003-07-23 | 2004-07-16 | Rapid disintegration and rapid dissolution tablet containing kakonein |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1270721C (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107987065A (en) * | 2017-12-20 | 2018-05-04 | 中国药科大学 | A kind of common amorphous substance of Puerarin niacinamide |
| CN115177594B (en) * | 2022-07-04 | 2023-08-15 | 武汉大学中南医院 | Acetinib pharmaceutical preparation and preparation method thereof |
-
2004
- 2004-07-16 CN CN 200410071712 patent/CN1270721C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1575798A (en) | 2005-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1186098C (en) | Tablets quickly disintegrated in the oral cavity | |
| CN1234230A (en) | Chewing article | |
| EP1022021A1 (en) | Quickly soluble solid preparations | |
| CN1911211A (en) | Solid oral prepn. of leishajilan | |
| CN100588400C (en) | Fast disintegrant containing paroxetine | |
| CN101461788B (en) | Phloroglucine orally disintegrating tablet and preparation method thereof | |
| CN101209249A (en) | Spaston orally disintegrating tablets and preparation thereof | |
| CN1943586A (en) | Oral disintegrating tablet using roxithromycin and ambroxol hydrochloride as active component and its preparing method and use | |
| CN100339081C (en) | Oral loratadine disintegrating tablet and its prepn | |
| CN1302772C (en) | Orally disintegrated sodium ferulate tablet and its prepn process | |
| CN1506043A (en) | Quickly disintegrating tablet containing cadotril | |
| CN1903183A (en) | Dispersion tablets of telbivudine and its prepn. method | |
| CN1270721C (en) | Rapid disintegration and rapid dissolution tablet containing kakonein | |
| CN101401796A (en) | Pramipexole orally disintegrating tablets and preparation method thereof | |
| CN1709246A (en) | Cilnidipine orally disintegrating tablet and its preparing method | |
| CN1586483A (en) | Oral disintegration tablet of silaenafil and its pharmaceutically receptible salt and its preparing method | |
| CN1582927A (en) | Oral disintegrants of nimodipine and their preparation | |
| CN1254240C (en) | Silibinin meglumine salt oral disintegration tablet preparation and its preparing method | |
| JPH11116465A (en) | Rapidly dissolvable preparation and its production | |
| CN1857342A (en) | Seabuckthorn preparation and its preparing process | |
| CN1857296A (en) | Medicine composition with roxithromycin and ambroxol hydrochloride as active components and its preparing method and use | |
| CN100394917C (en) | Bilobanoate oral-cavity disintegrating tablet and preparation method | |
| CN102370621A (en) | Solid preparation with cefotiam hexetil as active component | |
| CN1562013A (en) | Nisoldipine oral disintegration tablet for treating hypertension and preparing method | |
| CN1321645C (en) | Oral effervesce tablets for treating cardiovascular and cerebrovascular diseases, and prepn. method therefor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20060823 Termination date: 20100716 |